Source link : https://www.newshealth.biz/health-news/novel-drug-improved-symptoms-in-eosinophilic-esophagitis/
The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in patients with eosinophilic esophagitis at 24 weeks, a randomized phase III trial showed. Of the 430 patients, those receiving cendakimab had a least-squares mean change from baseline to week 24 of -6.1 dysphagia days compared with -4.2 dysphagia days in the placebo […]
Author : News Health
Publish date : 2024-10-30 19:18:36
Copyright for syndicated content belongs to the linked Source.